Drug Profile
LY 2811376
Alternative Names: LY2811376Latest Information Update: 30 Mar 2012
Price :
$50
*
At a glance
- Originator Eli Lilly and Company
- Class Antidementias; Pyrimidines; Small molecules; Thiazines
- Mechanism of Action Amyloid precursor protein secretase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Alzheimer's disease
Most Recent Events
- 31 Dec 2009 Development discontinued for Alzheimer's disease during 2009
- 31 Dec 2008 Phase-I clinical trials in Alzheimer's disease (in volunteers) in USA (PO)